Stay updated on Pembrolizumab with Targeted Therapy Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab with Targeted Therapy Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab with Targeted Therapy Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the web page.
    Difference
    0.1%
    Check dated 2024-06-13T22:49:50.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents an update in the efficacy testing of single-agent MK-3475 (pembrolizumab) in treating patients with chronic lymphocytic leukemia or other low-grade B-cell non-Hodgkin lymphomas, specifically focusing on the overall response rate.
    Difference
    0.1%
    Check dated 2024-06-06T14:48:13.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.' This change provides a more detailed explanation of the eligibility criteria for participation in the study.
    Difference
    53%
    Check dated 2024-05-22T21:36:55.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.5%
    Check dated 2024-04-30T22:52:34.000Z thumbnail image

Stay in the know with updates to Pembrolizumab with Targeted Therapy Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab with Targeted Therapy Clinical Trial page.